Basic Information
| LncRNA/CircRNA Name | TCONS_00020456 |
| Synonyms | TCON |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | RT-PCR , Western blot , in vitro knockdown etc. |
| Sample | glioblastoma tissues and normal tissues,human glioma cell lines(U251, U87) and normal human astrocytes (HA) |
| Expression Pattern | down-regulated |
| Function Description | TCON decreased significantly in GBM, and showed a coexpressional relationship with Smad2 and protein kinase C ? (PKC?). Overexpression of TCON reduced the proliferation on one hand and migration, invasion on the other.TCON also inhibited epithelial-mesenchymal transformation and glioma progression in vivo. In addition, we predicted a potential binding site and intersection that microRNAs targeting Smad2, PKC?, and TCON.Taken together, TCON, regarded as oncosuppressor, targeting the Smad2/PKC? axis plays a novel role in inhibiting the malignant progression of glioma. Moreover, the level of TCON can be used as a prognostic and diagnostic biomarker for GBM. |
| Pubmed ID | 31603255 |
| Year | 2019 |
| Title | Identification of Novel LncRNA Targeting Smad2/PKC? Signal Pathway to Negatively Regulate Malignant Progression of Glioblastoma |
External Links
| Links for TCONS_00020456 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |